A Potential Platform for Future Vaccine Trials Identifies a High Incidence of Symptomatic and Asymptomatic Influenza Infection Among Children Aged 6 to 23 Months in South Africa
Open Access
- 14 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (2) , e328-e336
Abstract
Background: Approaches for determining whether influenza vaccination prevents infection, attenuates illness, or both are important for developing improved vaccines. We estimated influenza infection incidence and evaluated symptom ascertainment methodologies in children to inform future vaccine trial design. Methods: We conducted a prospective cohort study among children aged 6 to 23 months from May to October 2022. Study nurses collected symptom and temperature data and midturbinate nasal swabs twice weekly irrespective of symptoms; caregivers entered symptom data daily and collected nasal swabs weekly. Samples were tested for influenza with polymerase chain reaction. Results: Of 230 healthy screened children, 93 were enrolled, of whom 87 (94%) completed 6-month follow-up. In total, 95% (4245/4476) of scheduled nurses, 90% (2045/2276) of caregiver swabs, 99% (92/93) of baseline blood collections, and 67% (9245/13 768) of scheduled symptom diaries were completed. Polymerase chain reaction–confirmed influenza incidence was 65% (60/93) for ≥1 infection; 11 (18%) individuals had 2 episodes and 1 (2%) had 3. Of 73 episodes, 55 (75%) had ≥1 symptom and 37 (51%) had fever (measured and/or reported). Median infection duration was 7 days (IQR, 4–9). Human RNase P gene was detected in 99% (2032/2045) of caregiver-collected swabs, through which 5 additional episodes were identified. Per episode, caregivers' diaries of reported and measured fever were 19% (25/73, 34%) and 11% (15/73, 21%) higher than nurse-reported (11/73, 15%) and nurse-measured (7/73, 10%) fever, respectively. Conclusions: The incidence of influenza infection was high and mainly symptomatic, suggesting that this platform could be suitable for future trials of vaccine efficacy and correlates of protection against infection and illness in children.Keywords
Funding Information
- National Institute for Communicable Diseases
- National Health Laboratory Service
- US Centers for Disease Control and Prevention (1U01IP001048)
This publication has 18 references indexed in Scilit:
- Key Issues as Wearable Digital Health Technologies Enter Clinical CareNew England Journal of Medicine, 2024
- Incidence and transmission of respiratory syncytial virus in urban and rural South Africa, 2017-2018Nature Communications, 2024
- SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21The Lancet Infectious Diseases, 2022
- Estimating Vaccine Efficacy Against Transmission via Effect on Viral LoadEpidemiology, 2021
- Interpreting vaccine efficacy trial results for infection and transmissionVaccine, 2021
- Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further researchVaccine, 2021
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Risk Factors and Attack Rates of Seasonal Influenza Infection: Results of the Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) Seroepidemiologic Cohort StudyThe Journal of Infectious Diseases, 2018
- Review ArticleEpidemiology, 2015
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009